Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 20 de 11.388
Filtrer
2.
Nutrients ; 16(11)2024 May 28.
Article de Anglais | MEDLINE | ID: mdl-38892586

RÉSUMÉ

Palmitoylethanolamide (PEA) emerged over the years as a promising approach in the management of chronic pain. Despite the fact that the efficacy of micron-size PEA formulations appears to be time-dependent, the optimal timing has not yet been elucidated. This systematic review and meta-analysis aim to estimate the possible advantage of an extended treatment in the relief of chronic pain. The literature search was conducted consulting scientific databases, to identify clinical trials in which micron-size PEA was administered for at least 60 days, and pain assessed by the Visual Analogue Scale (VAS) or Numeric Rating Scale (NRS). Nine studies matched the required criteria, for a total of 742 patients involved. The meta-analysis showed a statistically and clinically significant pain intensity reduction after 60 days of micron-size PEA supplementation, compared to 30 days (1.36 points, p < 0.01). The secondary analysis revealed a weighted NRS/VAS score decrease of 2.08 points within the first month of treatment. These two obtained scores corresponded to a 35.1% pain intensity reduction within the first month, followed by a further 35.4% during the second month. Overall, these results confirm the clinically relevant and time-depended pain-relieving effect of micron-size PEA and therefore the advantage of an extended treatment, especially in patient with incomplete pain management.


Sujet(s)
Amides , Douleur chronique , Éthanolamines , Acides palmitiques , Acides palmitiques/administration et posologie , Acides palmitiques/usage thérapeutique , Humains , Amides/administration et posologie , Éthanolamines/administration et posologie , Douleur chronique/traitement médicamenteux , Mesure de la douleur , Administration par voie orale , Résultat thérapeutique , Analgésiques/administration et posologie
3.
Arch Ital Urol Androl ; 96(2): 12582, 2024 Jun 27.
Article de Anglais | MEDLINE | ID: mdl-38934521

RÉSUMÉ

OBJECTIVE: The management of chronic prostatitis/ chronic pelvic pain syndrome type III (CP/CPPS) has been always considered complex due to several biopsychological factors underlying the disease. In this clinical study, we aimed to evaluate the efficacy of the treatment with Palmitoylethanolamide, Epilobium and Calendula extract in patients with CP/CPPS III. MATERIALS AND METHODS: From June 2023 to July 2023, we enrolled 45 consecutive patients affected by CP/CPPS type III in three different institution. We included patients aged between 18 and 75 years with symptoms of pelvic pain for 3 months or more before the study, a total National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) score ≥ 12 point and diagnosed with NIH category III, according to 4-glass test Meares-Stamey test. Patients were then allocated to receive rectal suppositories of PEA, Epilobium and Calendula, 1 suppository/ die for 1 month. All patients have been tested with standard urinalysis in order to assess urinary leukocytes (U-WBC). The primary endpoint of the study was the reduction of NIHCPSI. The secondary outcomes were the change of peak flow, post-void residual (PVR), IIEF-5, VAS score, PSA and decrease of U-WBC. RESULTS: A total of 45 patients concluded the study protocol. At baseline, the median age of all the patients included in the cohort was 49 years, the median PSA was 2.81 ng/ml, the median NIH-CPSI was 18.55, the median IIEF-5 was 18.27, the median U-WBC was 485.3/mmc, the median VAS score was 6.49, the median PVR was 26.5 ml and the median peak flow was 16.3 ml/s. After 1 month of therapy we observed a statistically significant improvement of NIH-CPSI, U-WBC, PSA, IIEF-5, peak flow, PVR and VAS. CONCLUSIONS: In this observational study, we showed the clinical efficacy of the treatment with PEA, Epilobium and Calendula, 1 suppository/die for 1 month, in patients with CP/CPPS III. The benefits of this treatment could be related to the reduction of inflammatory cells in the urine that could imply a reduction of inflammatory cytokines. These results should be confirmed in further studies with greater sample size.


Sujet(s)
Amides , Calendula , Épilobium , Éthanolamines , Acides palmitiques , Extraits de plantes , Prostatite , Humains , Mâle , Adulte d'âge moyen , Adulte , Prostatite/traitement médicamenteux , Suppositoires , Amides/administration et posologie , Amides/usage thérapeutique , Sujet âgé , Acides palmitiques/administration et posologie , Acides palmitiques/usage thérapeutique , Résultat thérapeutique , Jeune adulte , Éthanolamines/administration et posologie , Éthanolamines/usage thérapeutique , Extraits de plantes/administration et posologie , Extraits de plantes/usage thérapeutique , Adolescent , Maladie chronique , Douleur pelvienne/traitement médicamenteux , Douleur pelvienne/étiologie
4.
Chemosphere ; 361: 142495, 2024 Aug.
Article de Anglais | MEDLINE | ID: mdl-38823427

RÉSUMÉ

The cationic surfactant triethanolamine-based esterquat (TEAQ) is a main ingredient in commercial fabric softeners and is produced and used in large quantities. However, little information is available for its occurrence in the environment, particularly in sediments. Here, we developed an analytical method for quantifying TEAQ in sediment and investigated TEAQ contamination in Japanese river and lake sediments. In our analytical method, TEAQ concentrations were measured by liquid chromatography-tandem mass spectrometry using a polymer-based size-exclusion column, which resulted in excellent peak shapes. TEAQ was detected at significant levels in procedural blanks, resulting in a method limit of detection in the sediment of 8.9-97 µg/kg-dry for TEAQ monoesters and 0.6-24 µg/kg-dry for TEAQ diesters. TEAQ was detected in 22 out of 26 sediment samples, with the sum of all homologue concentrations being up to 1340 µg/kg-dry. The concentration of TEAQ in sediments was high at locations where the concentrations of benzalkoniums and the organic carbon content were also high. TEAQ was detected in 8 out of 14 commercial fabric softeners at concentrations of 1.7-7.4 wt%. TEAQ homologues containing only saturated fatty acids accounted for 83 ± 5% of the total TEAQ in the sediments, whereas those with unsaturated fatty acids accounted for 71 ± 14% of the total TEAQ in a commercial technical mixture and the softener products. The results of this study will be useful for the environmental risk assessment of esterquats.


Sujet(s)
Surveillance de l'environnement , Sédiments géologiques , Rivières , Spectrométrie de masse en tandem , Polluants chimiques de l'eau , Sédiments géologiques/composition chimique , Polluants chimiques de l'eau/analyse , Surveillance de l'environnement/méthodes , Rivières/composition chimique , Éthanolamines/analyse , Tensioactifs/analyse , Tensioactifs/composition chimique , Chromatographie en phase liquide , Lacs/composition chimique
5.
Malar J ; 23(1): 184, 2024 Jun 12.
Article de Anglais | MEDLINE | ID: mdl-38867217

RÉSUMÉ

BACKGROUND: Malaria remains a major global health problem although there was a remarkable achievement between 2000 and 2015. Malaria drug resistance, along with several other factors, presents a significant challenge to malaria control and elimination efforts. Numerous countries in sub-Saharan Africa have documented the presence of confirmed or potential markers of partial resistance against artemisinin, the drug of choice for the treatment of uncomplicated Plasmodium falciparum malaria. The World Health Organization (WHO) recommends regular surveillance of artemisinin therapeutic efficacy to inform policy decisions. METHODS: This study aimed to evaluate the therapeutic efficacy of artemether-lumefantrine (AL), which is the first-line treatment for uncomplicated P. falciparum malaria in Ethiopia since 2004. Using a single-arm prospective evaluation design, the study assessed the clinical and parasitological responses of patients with uncomplicated P. falciparum malaria in Metehara Health Centre, central-east Ethiopia. Out of 2332 malaria suspects (1187 males, 1145 females) screened, 80 (50 males, 30 females) were enrolled, followed up for 28 days, and 73 (44 males, 29 females) completed the follow up. The study was conducted and data was analysed by employing the per-protocol and Kaplan-Meier analyses following the WHO Malaria Therapeutic Efficacy Evaluation Guidelines 2009. RESULTS: The results indicated rapid parasite clearance and resolution of clinical symptoms, with all patients achieving complete recovery from asexual parasitaemia and fever by day (D) 3. The prevalence of gametocytes decreased from 6.3% on D0 to 2.5% on D2, D3, D7, and ultimately achieving complete clearance afterward. CONCLUSION: The overall cure rate for AL treatment was 100%, demonstrating its high efficacy in effectively eliminating malaria parasites in patients. No serious adverse events related to AL treatment were reported during the study, suggesting its safety and tolerability among the participants. These findings confirm that AL remains a highly efficacious treatment for uncomplicated P. falciparum malaria in the study site after 20 years of its introduction in Ethiopia.


Sujet(s)
Antipaludiques , Association d'artéméther et de luméfantrine , Paludisme à Plasmodium falciparum , Humains , Éthiopie , Paludisme à Plasmodium falciparum/traitement médicamenteux , Association d'artéméther et de luméfantrine/usage thérapeutique , Mâle , Femelle , Antipaludiques/usage thérapeutique , Antipaludiques/effets indésirables , Adulte , Adolescent , Jeune adulte , Enfant d'âge préscolaire , Enfant , Études prospectives , Adulte d'âge moyen , Nourrisson , Artémisinines/usage thérapeutique , Artémisinines/effets indésirables , Fluorènes/usage thérapeutique , Fluorènes/effets indésirables , Résultat thérapeutique , Éthanolamines/usage thérapeutique , Éthanolamines/effets indésirables , Sujet âgé , Association médicamenteuse , Plasmodium falciparum/effets des médicaments et des substances chimiques
6.
Nutr J ; 23(1): 61, 2024 Jun 12.
Article de Anglais | MEDLINE | ID: mdl-38862960

RÉSUMÉ

BACKGROUND: The Mediterranean diet (MedDiet) has demonstrated efficacy in preventing age-related cognitive decline and modulating plasma concentrations of endocannabinoids (eCBs) and N-acylethanolamines (NAEs, or eCB-like compounds), which are lipid mediators involved in multiple neurological disorders and metabolic processes. Hypothesizing that eCBs and NAEs will be biomarkers of a MedDiet intervention and will be related to the cognitive response, we investigated this relationship according to sex and apolipoprotein E (APOE) genotype, which may affect eCBs and cognitive performance. METHODS: This was a prospective cohort study of 102 participants (53.9% women, 18.8% APOE-ɛ4 carriers, aged 65.6 ± 4.5 years) from the PREDIMED-Plus-Cognition substudy, who were recruited at the Hospital del Mar Research Institute (Barcelona). All of them presented metabolic syndrome plus overweight/obesity (inclusion criteria of the PREDIMED-Plus) and normal cognitive performance at baseline (inclusion criteria of this substudy). A comprehensive battery of neuropsychological tests was administered at baseline and after 1 and 3 years. Plasma concentrations of eCBs and NAEs, including 2-arachidonoylglycerol (2-AG), anandamide (AEA), oleoylethanolamide (OEA), palmitoylethanolamide (PEA), and N-docosahexaenoylethanolamine (DHEA), were also monitored. Baseline cognition, cognitive changes, and the association between eCBs/NAEs and cognition were evaluated according to gender (crude models), sex (adjusted models), and APOE genotype. RESULTS: At baseline, men had better executive function and global cognition than women (the effect size of gender differences was - 0.49, p = 0.015; and - 0.42, p = 0.036); however, these differences became nonsignificant in models of sex differences. After 3 years of MedDiet intervention, participants exhibited modest improvements in memory and global cognition. However, greater memory changes were observed in men than in women (Cohen's d of 0.40 vs. 0.25; p = 0.017). In men and APOE-ε4 carriers, 2-AG concentrations were inversely associated with baseline cognition and cognitive changes, while in women, cognitive changes were positively linked to changes in DHEA and the DHEA/AEA ratio. In men, changes in the OEA/AEA and OEA/PEA ratios were positively associated with cognitive changes. CONCLUSIONS: The MedDiet improved participants' cognitive performance but the effect size was small and negatively influenced by female sex. Changes in 2-AG, DHEA, the OEA/AEA, the OEA/PEA and the DHEA/AEA ratios were associated with cognitive changes in a sex- and APOE-dependent fashion. These results support the modulation of the endocannabinoid system as a potential therapeutic approach to prevent cognitive decline in at-risk populations. TRIAL REGISTRATION: ISRCTN89898870.


Sujet(s)
Cognition , Régime méditerranéen , Endocannabinoïdes , Génotype , Syndrome métabolique X , Sujet âgé , Femelle , Humains , Mâle , Adulte d'âge moyen , Amides , Apolipoprotéines E/génétique , Acides arachidoniques/sang , Marqueurs biologiques/sang , Cognition/physiologie , Régime méditerranéen/statistiques et données numériques , Endocannabinoïdes/sang , Éthanolamines/sang , Glycérides/sang , Syndrome métabolique X/génétique , Acides oléiques/sang , Acides palmitiques/sang , Amides gras polyinsaturés N-alkylés/sang , Études prospectives , Facteurs sexuels
7.
J Proteome Res ; 23(6): 2054-2066, 2024 Jun 07.
Article de Anglais | MEDLINE | ID: mdl-38775738

RÉSUMÉ

The metabolites and microbiota in tongue coating display distinct characteristics in certain digestive disorders, yet their relationship with colorectal cancer (CRC) remains unexplored. Here, we employed liquid chromatography coupled with tandem mass spectrometry to analyze the lipid composition of tongue coating using a nontargeted approach in 30 individuals with colorectal adenomas (CRA), 32 with CRC, and 30 healthy controls (HC). We identified 21 tongue coating lipids that effectively distinguished CRC from HC (AUC = 0.89), and 9 lipids that differentiated CRC from CRA (AUC = 0.9). Furthermore, we observed significant alterations in the tongue coating lipid composition in the CRC group compared to HC/CRA groups. As the adenoma-cancer sequence progressed, there was an increase in long-chain unsaturated triglycerides (TG) levels and a decrease in phosphatidylethanolamine plasmalogen (PE-P) levels. Furthermore, we noted a positive correlation between N-acyl ornithine (NAOrn), sphingomyelin (SM), and ceramide phosphoethanolamine (PE-Cer), potentially produced by members of the Bacteroidetes phylum. The levels of inflammatory lipid metabolite 12-HETE showed a decreasing trend with colorectal tumor progression, indicating the potential involvement of tongue coating microbiota and tumor immune regulation in early CRC development. Our findings highlight the potential utility of tongue coating lipid analysis as a noninvasive tool for CRC diagnosis.


Sujet(s)
Tumeurs colorectales , Lipidomique , Phosphatidyléthanolamine , Spectrométrie de masse en tandem , Langue , Humains , Tumeurs colorectales/métabolisme , Tumeurs colorectales/microbiologie , Lipidomique/méthodes , Mâle , Femelle , Langue/microbiologie , Langue/métabolisme , Langue/anatomopathologie , Langue/composition chimique , Adulte d'âge moyen , Spectrométrie de masse en tandem/méthodes , Phosphatidyléthanolamine/métabolisme , Phosphatidyléthanolamine/analyse , Sujet âgé , Chromatographie en phase liquide , Lipides/analyse , Lipides/composition chimique , Triglycéride/métabolisme , Triglycéride/analyse , Adénomes/métabolisme , Adénomes/microbiologie , Sphingomyéline/analyse , Sphingomyéline/métabolisme , Acide éicosatétraénoïque-5,8,10,14 hydroxy-12/métabolisme , Acide éicosatétraénoïque-5,8,10,14 hydroxy-12/composition chimique , Acétalphosphatides/analyse , Acétalphosphatides/métabolisme , Acétalphosphatides/composition chimique , Études cas-témoins , Éthanolamines/métabolisme , Éthanolamines/analyse , Éthanolamines/composition chimique , Céramides/métabolisme , Céramides/analyse , Adulte
8.
Lancet Microbe ; 5(7): 633-644, 2024 Jul.
Article de Anglais | MEDLINE | ID: mdl-38705163

RÉSUMÉ

BACKGROUND: Artemether-lumefantrine is widely used for uncomplicated Plasmodium falciparum malaria; sulfadoxine-pyrimethamine plus amodiaquine is used for seasonal malaria chemoprevention. We aimed to determine the efficacy of artemether-lumefantrine with and without primaquine and sulfadoxine-pyrimethamine plus amodiaquine with and without tafenoquine for reducing gametocyte carriage and transmission to mosquitoes. METHODS: In this phase 2, single-blind, randomised clinical trial conducted in Ouelessebougou, Mali, asymptomatic individuals aged 10-50 years with P falciparum gametocytaemia were recruited from the community and randomly assigned (1:1:1:1) to receive either artemether-lumefantrine, artemether-lumefantrine with a single dose of 0·25 mg/kg primaquine, sulfadoxine-pyrimethamine plus amodiaquine, or sulfadoxine-pyrimethamine plus amodiaquine with a single dose of 1·66 mg/kg tafenoquine. All trial staff other than the pharmacist were masked to group allocation. Participants were not masked to group allocation. Randomisation was done with a computer-generated randomisation list and concealed with sealed, opaque envelopes. The primary outcome was the median within-person percent change in mosquito infection rate in infectious individuals from baseline to day 2 (artemether-lumefantrine groups) or day 7 (sulfadoxine-pyrimethamine plus amodiaquine groups) after treatment, assessed by direct membrane feeding assay. All participants who received any trial drug were included in the safety analysis. This study is registered with ClinicalTrials.gov, NCT05081089. FINDINGS: Between Oct 13 and Dec 16, 2021, 1290 individuals were screened and 80 were enrolled and randomly assigned to one of the four treatment groups (20 per group). The median age of participants was 13 (IQR 11-20); 37 (46%) of 80 participants were female and 43 (54%) were male. In individuals who were infectious before treatment, the median percentage reduction in mosquito infection rate 2 days after treatment was 100·0% (IQR 100·0-100·0; n=19; p=0·0011) with artemether-lumefantrine and 100·0% (100·0-100·0; n=19; p=0·0001) with artemether-lumefantrine with primaquine. Only two individuals who were infectious at baseline infected mosquitoes on day 2 after artemether-lumefantrine and none at day 5. By contrast, the median percentage reduction in mosquito infection rate 7 days after treatment was 63·6% (IQR 0·0-100·0; n=20; p=0·013) with sulfadoxine-pyrimethamine plus amodiaquine and 100% (100·0-100·0; n=19; p<0·0001) with sulfadoxine-pyrimethamine plus amodiaquine with tafenoquine. No grade 3-4 or serious adverse events occurred. INTERPRETATION: These data support the effectiveness of artemether-lumefantrine alone for preventing nearly all mosquito infections. By contrast, there was considerable post-treatment transmission after sulfadoxine-pyrimethamine plus amodiaquine; therefore, the addition of a transmission-blocking drug might be beneficial in maximising its community impact. FUNDING: Bill & Melinda Gates Foundation.


Sujet(s)
Amodiaquine , Antipaludiques , Association d'artéméther et de luméfantrine , Association médicamenteuse , Fluorènes , Paludisme à Plasmodium falciparum , Plasmodium falciparum , Primaquine , Pyriméthamine , Sulfadoxine , Humains , Antipaludiques/usage thérapeutique , Antipaludiques/administration et posologie , Pyriméthamine/usage thérapeutique , Pyriméthamine/administration et posologie , Amodiaquine/usage thérapeutique , Amodiaquine/administration et posologie , Sulfadoxine/usage thérapeutique , Sulfadoxine/administration et posologie , Mâle , Adulte , Femelle , Adolescent , Enfant , Paludisme à Plasmodium falciparum/transmission , Paludisme à Plasmodium falciparum/prévention et contrôle , Paludisme à Plasmodium falciparum/traitement médicamenteux , Paludisme à Plasmodium falciparum/épidémiologie , Méthode en simple aveugle , Adulte d'âge moyen , Primaquine/usage thérapeutique , Primaquine/administration et posologie , Association d'artéméther et de luméfantrine/usage thérapeutique , Association d'artéméther et de luméfantrine/administration et posologie , Jeune adulte , Fluorènes/administration et posologie , Fluorènes/usage thérapeutique , Mali/épidémiologie , Plasmodium falciparum/effets des médicaments et des substances chimiques , Artémisinines/administration et posologie , Artémisinines/usage thérapeutique , Aminoquinoléines/administration et posologie , Aminoquinoléines/usage thérapeutique , Aminoquinoléines/effets indésirables , Éthanolamines/administration et posologie , Éthanolamines/usage thérapeutique , Animaux , Association de médicaments
10.
Int J Mol Sci ; 25(9)2024 Apr 27.
Article de Anglais | MEDLINE | ID: mdl-38732008

RÉSUMÉ

Neuropathy affects 7-10% of the general population and is caused by a lesion or disease of the somatosensory system. The limitations of current therapies highlight the necessity of a new innovative approach to treating neuropathic pain (NP) based on the close correlation between oxidative stress, inflammatory process, and antioxidant action. The advantageous outcomes of a novel combination composed of Hop extract, Propolis, Ginkgo Biloba, Vitamin B, and palmitoylethanolamide (PEA) used as a treatment was evaluated in this study. To assess the absorption and biodistribution of the combination, its bioavailability was first examined in a 3D intestinal barrier model that replicated intestinal absorption. Further, a 3D nerve tissue model was developed to study the biological impacts of the combination during the essential pathways involved in NP. Our findings show that the combination could cross the intestinal barrier and reach the peripheral nervous system, where it modulates the oxidative stress, inflammation levels, and myelination mechanism (increased NRG, MPZ, ERB, and p75 levels) under Schwann cells damaging. This study proves the effectiveness of Ginkgo Biloba, Propolis, Hop extract, Vitamin B, and PEA in avoiding nerve damage and suggests a potential alternative nutraceutical treatment for NP and neuropathies.


Sujet(s)
Amides , Compléments alimentaires , Éthanolamines , Névralgie , Acides palmitiques , Plantes médicinales , Éthanolamines/pharmacologie , Acides palmitiques/pharmacologie , Acides palmitiques/administration et posologie , Animaux , Névralgie/traitement médicamenteux , Amides/pharmacologie , Amides/composition chimique , Plantes médicinales/composition chimique , Polyphénols/pharmacologie , Polyphénols/composition chimique , Stress oxydatif/effets des médicaments et des substances chimiques , Extraits de plantes/pharmacologie , Extraits de plantes/composition chimique , Rats , Mâle , Antioxydants/pharmacologie , Ginkgo biloba/composition chimique , Humains
11.
Antimicrob Agents Chemother ; 68(5): e0009324, 2024 May 02.
Article de Anglais | MEDLINE | ID: mdl-38597636

RÉSUMÉ

Capillary samples offer practical benefits compared with venous samples for the measurement of drug concentrations, but the relationship between the two measures varies between different drugs. We measured the concentrations of lumefantrine, mefloquine, piperaquine in 270 pairs of venous plasma and concurrent capillary plasma samples collected from 270 pregnant women with uncomplicated falciparum or vivax malaria. The median and range of venous plasma concentrations included in this study were 447.5 ng/mL (8.81-3,370) for lumefantrine (day 7, n = 76, median total dose received 96.0 mg/kg), 17.9 ng/mL (1.72-181) for desbutyl-lumefantrine, 1,885 ng/mL (762-4,830) for mefloquine (days 3-21, n = 90, median total dose 24.9 mg/kg), 641 ng/mL (79.9-1,950) for carboxy-mefloquine, and 51.8 ng/mL (3.57-851) for piperaquine (days 3-21, n = 89, median total dose 52.2 mg/kg). Although venous and capillary plasma concentrations showed a high correlation (Pearson's correlation coefficient: 0.90-0.99) for all antimalarials and their primary metabolites, they were not directly interchangeable. Using the concurrent capillary plasma concentrations and other variables, the proportions of venous plasma samples predicted within a ±10% precision range was 34% (26/76) for lumefantrine, 36% (32/89) for desbutyl-lumefantrine, 74% (67/90) for mefloquine, 82% (74/90) for carboxy-mefloquine, and 24% (21/89) for piperaquine. Venous plasma concentrations of mefloquine, but not lumefantrine and piperaquine, could be predicted by capillary plasma samples with an acceptable level of agreement. Capillary plasma samples can be utilized for pharmacokinetic and clinical studies, but caution surrounding cut-off values is required at the individual level.CLINICAL TRIALSThis study is registered with ClinicalTrials.gov as NCT01054248.


Sujet(s)
Antipaludiques , Luméfantrine , Paludisme à Plasmodium falciparum , Paludisme à Plasmodium vivax , Méfloquine , Pipérazines , Quinoléines , Humains , Femelle , Méfloquine/sang , Méfloquine/usage thérapeutique , Méfloquine/pharmacocinétique , Antipaludiques/sang , Antipaludiques/usage thérapeutique , Antipaludiques/pharmacocinétique , Grossesse , Quinoléines/sang , Quinoléines/pharmacocinétique , Quinoléines/usage thérapeutique , Luméfantrine/usage thérapeutique , Luméfantrine/sang , Paludisme à Plasmodium falciparum/traitement médicamenteux , Paludisme à Plasmodium falciparum/sang , Adulte , Paludisme à Plasmodium vivax/traitement médicamenteux , Paludisme à Plasmodium vivax/sang , Jeune adulte , Éthanolamines/sang , Éthanolamines/pharmacocinétique , Éthanolamines/usage thérapeutique , Fluorènes/sang , Fluorènes/usage thérapeutique , Fluorènes/pharmacocinétique , Adolescent
12.
J Bacteriol ; 206(5): e0043523, 2024 May 23.
Article de Anglais | MEDLINE | ID: mdl-38661375

RÉSUMÉ

Acinetobacter baumannii is highly resistant to antimicrobial agents, and XDR strains have become widespread. A. baumannii has developed resistance to colistin, which is considered the last resort against XDR Gram-negative bacteria, mainly caused by lipooligosaccharide (LOS) phosphoethanolamine (pEtN) and/or galactosamine (GalN) modifications induced by mutations that activate the two-component system (TCS) pmrAB. Although PmrAB of A. baumannii has been recognized as a drug resistance factor, its function as TCS, including its regulatory genes and response factors, has not been fully elucidated. In this study, to clarify the function of PmrAB as TCS, we elucidated the regulatory genes (regulon) of PmrAB via transcriptome analysis using pmrAB-activated mutant strains. We discovered that PmrAB responds to low pH, Fe2+, Zn2+, and Al3+. A. baumannii selectively recognizes Fe2+ rather than Fe3+, and a novel region ExxxE, in addition to the ExxE motif sequence, is involved in the environmental response. Furthermore, PmrAB participates in the phosphoethanolamine modification of LOS on the bacterial surface in response to metal ions such as Al3+, contributing to the attenuation of Al3+ toxicity and development of resistance to colistin and polymyxin B in A. baumannii. This study demonstrates that PmrAB in A. baumannii not only regulates genes that play an important role in drug resistance but is also involved in responses to environmental stimuli such as metal ions and pH, and this stimulation induces LOS modification. This study reveals the importance of PmrAB in the environmental adaptation and antibacterial resistance emergence mechanisms of A. baumannii. IMPORTANCE: Antimicrobial resistance (AMR) is a pressing global issue in human health. Acinetobacter baumannii is notably high on the World Health Organization's list of bacteria for which new antimicrobial agents are urgently needed. Colistin is one of the last-resort drugs used against extensively drug-resistant (XDR) Gram-negative bacteria. However, A. baumannii has become increasingly resistant to colistin, primarily by modifying its lipooligosaccharide (LOS) via activating mutations in the two-component system (TCS) PmrAB. This study comprehensively elucidates the detailed mechanism of drug resistance of PmrAB in A. baumannii as well as its biological functions. Understanding the molecular biology of these molecules, which serve as drug resistance factors and are involved in environmental recognition mechanisms in bacteria, is crucial for developing fundamental solutions to the AMR problem.


Sujet(s)
Acinetobacter baumannii , Protéines bactériennes , Éthanolamines , Régulation de l'expression des gènes bactériens , Lipopolysaccharides , Acinetobacter baumannii/génétique , Acinetobacter baumannii/effets des médicaments et des substances chimiques , Acinetobacter baumannii/métabolisme , Lipopolysaccharides/métabolisme , Protéines bactériennes/génétique , Protéines bactériennes/métabolisme , Éthanolamines/pharmacologie , Éthanolamines/métabolisme , Antibactériens/pharmacologie , Métaux/métabolisme , Métaux/pharmacologie , Facteurs de transcription
13.
Shock ; 61(6): 915-923, 2024 Jun 01.
Article de Anglais | MEDLINE | ID: mdl-38662592

RÉSUMÉ

ABSTRACT: ß 3 -adrenergic receptor (ß 3 -AR) has been proposed as a new therapy for several myocardial diseases. However, the effect of ß 3 -AR activation on sepsis-induced myocardial apoptosis is unclear. Here, we investigated the effect of ß 3 -AR activation on the cardiomyocyte apoptosis and cardiac dysfunction in cecal ligation and puncture (CLP)-operated rats and lipopolysaccharide (LPS)-treated cardiomyocytes. We found that ß 3 -AR existed both in adult rat ventricular myocytes (ARVMs) and H9c2 cells. The expression of ß 3 -AR was upregulated in LPS-treated ARVMs and the heart of CLP rats. Pretreatment with ß 3 -AR agonist, BRL37344, inhibited LPS-induced cardiomyocyte apoptosis and caspase-3, -8, and -9 activation in ARVMs. BRL37344 also reduced apoptosis and increased the protein levels of PI3K, p-Akt Ser473 and p-eNOS Ser1177 in LPS-treated H9c2 cells. Inhibition of PI3K using LY294002 abolished the inhibitory effect of BRL37344 on LPS-induced caspase-3, -8, and -9 activation in H9c2 cells. Furthermore, administration of ß 3 -AR antagonist, SR59230A (5 mg/kg), significantly decreased the maximum rate of left ventricular pressure rise (+dP/dt) in CLP-induced septic rats. SR59230A not only increased myocardial apoptosis, reduced p-Akt Ser473 and Bcl-2 contents, but also increased mitochondrial Bax, cytoplasm cytochrome c, cleaved caspase-9, and cleaved caspase-3 levels of the myocardium in septic rats. These results suggest that endogenous ß 3 -AR activation alleviates sepsis-induced cardiomyocyte apoptosis via PI3K/Akt signaling pathway and maintains intrinsic myocardial systolic function in sepsis.


Sujet(s)
Apoptose , Myocytes cardiaques , Phosphatidylinositol 3-kinases , Protéines proto-oncogènes c-akt , Rat Sprague-Dawley , Récepteurs bêta-3 adrénergiques , Sepsie , Transduction du signal , Animaux , Myocytes cardiaques/métabolisme , Myocytes cardiaques/effets des médicaments et des substances chimiques , Myocytes cardiaques/anatomopathologie , Apoptose/effets des médicaments et des substances chimiques , Sepsie/métabolisme , Rats , Protéines proto-oncogènes c-akt/métabolisme , Phosphatidylinositol 3-kinases/métabolisme , Transduction du signal/effets des médicaments et des substances chimiques , Mâle , Récepteurs bêta-3 adrénergiques/métabolisme , Lipopolysaccharides/toxicité , Agonistes des récepteurs bêta-3 adrénergiques/pharmacologie , Lignée cellulaire , Éthanolamines
14.
Mol Genet Genomics ; 299(1): 43, 2024 Apr 10.
Article de Anglais | MEDLINE | ID: mdl-38598031

RÉSUMÉ

Phosphatidylserine (PS) is important for maintaining growth, cytoskeleton, and various functions in yeast; however, its role in stress responses is poorly understood. In Schizosaccharomyces pombe, the PS synthase deletion (pps1∆) mutant shows defects in growth, morphology, cytokinesis, actin cytoskeleton, and cell wall integrity, and these phenotypes are rescued by ethanolamine supplementation. Here, we evaluated the role of Pps1 in the salt stress response in S. pombe. We found that pps1∆ cells are sensitive to salt stresses such as KCl and CaCl2 even in the presence of ethanolamine. Loss of the functional cAMP-dependent protein kinase (git3∆ or pka1∆) or phospholipase B Plb1 (plb1∆) enhanced the salt stress-sensitive phenotype in pps1∆ cells. Green fluorescent protein (GFP)-Pps1 was localized at the plasma membrane and endoplasmic reticulum regardless of the stress conditions. In pka1∆ cells, GFP-Pps1 was accumulated around the nucleus under the KCl stress. Pka1 was localized in the nucleus and the cytoplasm under normal conditions and transferred from the nucleus to the cytoplasm under salt-stress conditions. Pka1 translocated from the nucleus to the cytoplasm during CaCl2 stress in the wild-type cells, while it remained localized in the nucleus in pps1∆ cells. Expression and phosphorylation of Pka1-GFP were not changed in pps1∆ cells. Our results demonstrate that Pps1 plays an important role in the salt stress response in S. pombe.


Sujet(s)
Schizosaccharomyces , Schizosaccharomyces/génétique , CDPdiacylglycerol-serine O-phosphatidyltransferase/génétique , Chlorure de calcium , Stress salin/génétique , Éthanolamine , Éthanolamines , Protéines à fluorescence verte
15.
PeerJ ; 12: e17183, 2024.
Article de Anglais | MEDLINE | ID: mdl-38560476

RÉSUMÉ

Background: PEBP (phosphatidyl ethanolamine-binding protein) is widely found in eukaryotes including plants, animals and microorganisms. In plants, the PEBP family plays vital roles in regulating flowering time and morphogenesis and is highly associated to agronomic traits and yields of crops, which has been identified and characterized in many plant species but not well studied in Tartary buckwheat (Fagopyrum tataricum Gaertn.), an important coarse food grain with medicinal value. Methods: Genome-wide analysis of FtPEBP gene family members in Tartary buckwheat was performed using bioinformatic tools. Subcellular localization analysis was performed by confocal microscopy. The expression levels of these genes in leaf and inflorescence samples were analyzed using qRT-PCR. Results: Fourteen Fagopyrum tataricum PEBP (FtPEBP) genes were identified and divided into three sub-clades according to their phylogenetic relationships. Subcellular localization analysis of the FtPEBP proteins in tobacco leaves indicated that FT- and TFL-GFP fusion proteins were localized in both the nucleus and cytoplasm. Gene structure analysis showed that most FtPEBP genes contain four exons and three introns. FtPEBP genes are unevenly distributed in Tartary buckwheat chromosomes. Three tandem repeats were found among FtFT5/FtFT6, FtMFT1/FtMFT2 and FtTFL4/FtTFL5. Five orthologous gene pairs were detected between F. tataricum and F. esculentum. Seven light-responsive, nine hormone-related and four stress-responsive elements were detected in FtPEBPs promoters. We used real-time PCR to investigate the expression levels of FtPEBPs among two flowering-type cultivars at floral transition time. We found FtFT1/FtFT3 were highly expressed in leaf and young inflorescence of early-flowering type, whereas they were expressed at very low levels in late-flowering type cultivars. Thus, we deduced that FtFT1/FtFT3 may be positive regulators for flowering and yield of Tartary buckwheat. These results lay an important foundation for further studies on the functions of FtPEBP genes which may be utilized for yield improvement.


Sujet(s)
Fagopyrum , Phylogenèse , Fagopyrum/génétique , Protéines végétales/génétique , Génome végétal , Éthanolamines/métabolisme
16.
Biomed Pharmacother ; 174: 116531, 2024 May.
Article de Anglais | MEDLINE | ID: mdl-38574624

RÉSUMÉ

N-acylethanolamines (NAEs) are endogenous lipid-signalling molecules involved in inflammation and energy metabolism. The potential pharmacological effect of NAE association in managing inflammation-based metabolic disorders is unexplored. To date, targeting liver-adipose axis can be considered a therapeutic approach for the treatment of obesity and related dysfunctions. Here, we investigated the metabolic effect of OLALIAMID® (OLA), an olive oil-derived NAE mixture, in limiting liver and adipose tissue (AT) dysfunction of high-fat diet (HFD)-fed mice. OLA reduced body weight and fat mass in obese mice, decreasing insulin resistance (IR), as shown by homeostasis model assessment index, and leptin/adiponectin ratio, a marker of adipocyte dysfunction. OLA improved serum lipid and hepatic profile and the immune/inflammatory pattern of metainflammation. In liver of HFD mice, OLA treatment counteracted glucose and lipid dysmetabolism, restoring insulin signalling (phosphorylation of AKT and AMPK), and reducing mRNAs of key markers of fatty acid accumulation. Furthermore, OLA positively affected AT function deeply altered by HFD by reprogramming of genes involved in thermogenesis of interscapular brown AT (iBAT) and subcutaneous white AT (scWAT), and inducing the beigeing of scWAT. Notably, the NAE mixture reduced inflammation in iBAT and promoted M1-to-M2 macrophage shift in scWAT of obese mice. The tissue and systemic anti-inflammatory effects of OLA and the increased expression of glucose transporter 4 in scWAT contributed to the improvement of gluco-lipid toxicity and insulin sensitivity. In conclusion, we demonstrated that this olive oil-derived NAE mixture is a valid nutritional strategy to counteract IR and obesity acting on liver-AT crosstalk, restoring both hepatic and AT function and metabolism.


Sujet(s)
Adipocytes , Tissu adipeux , Alimentation riche en graisse , Éthanolamines , Insulinorésistance , Foie , Souris de lignée C57BL , Obésité , Animaux , Foie/effets des médicaments et des substances chimiques , Foie/métabolisme , Mâle , Éthanolamines/pharmacologie , Adipocytes/effets des médicaments et des substances chimiques , Adipocytes/métabolisme , Obésité/traitement médicamenteux , Obésité/métabolisme , Souris , Alimentation riche en graisse/effets indésirables , Tissu adipeux/effets des médicaments et des substances chimiques , Tissu adipeux/métabolisme , Souris obèse , Métabolisme lipidique/effets des médicaments et des substances chimiques
17.
Sci Rep ; 14(1): 9459, 2024 04 24.
Article de Anglais | MEDLINE | ID: mdl-38658668

RÉSUMÉ

Analysis of endocannabinoids (ECs) and N-acylethanolamines (NAEs) in hair is assumed to retrospectively assess long-term EC/NAE concentrations. To inform their use, this study investigated stability of EC/NAE hair concentrations in mothers, fathers, and their children across the perinatal period as well as associations between family members. In a prospective cohort study, EC (AEA, 1-AG/2-AG) and NAE (SEA, PEA, OEA) levels were quantified in hair samples taken four times in mothers (n = 336) and their partners (n = 225) from pregnancy to two years postpartum and in offspring (n = 319) from shortly after birth to two years postpartum. Across the perinatal period, maternal and paternal hair ECs/NAEs showed poor multiple-test consistency (16-36%) and variable relative stability, as well as inconsistent absolute stability for mothers. Regarding children, hair ECs/NAEs evidenced poor multiple-test consistency (4-19%), no absolute stability, and either no or variable relative stability. Hair ECs/NAEs showed small to medium significant associations across the perinatal period within couples and parent-child dyads. Findings suggest hair ECs/NAEs during the perinatal period possess variable stability in adults, albeit more stability in fathers than mothers in this time. This highlights the need to further investigate factors associated with changes in hair ECs/NAEs across time. The first two years of life may be a dynamic phase for the endocannabinoid system in children, potentially characterized by complex within-family correspondence that requires further systematic investigation.


Sujet(s)
Endocannabinoïdes , Éthanolamines , Pères , Poils , Mères , Humains , Endocannabinoïdes/métabolisme , Endocannabinoïdes/analyse , Femelle , Poils/composition chimique , Poils/métabolisme , Mâle , Éthanolamines/métabolisme , Éthanolamines/analyse , Adulte , Grossesse , Enfant d'âge préscolaire , Nourrisson , Études prospectives , Nouveau-né , Enfant
18.
Malar J ; 23(1): 125, 2024 Apr 29.
Article de Anglais | MEDLINE | ID: mdl-38685044

RÉSUMÉ

BACKGROUND: Despite efforts made to reduce morbidity and mortality associated with malaria, especially in sub-Saharan Africa, malaria continues to be a public health concern that requires innovative efforts to reach the WHO-set zero malaria agenda. Among the innovations is the use of artemisinin-based combination therapy (ACT) that is effective against Plasmodium falciparum. Generic artemether-lumefantrine (AL) is used to treat uncomplicated malaria after appropriate diagnosis. AL is metabolized by the cytochrome P450 family of enzymes, such as CYP2B6, CYP3A4 and CYP3A5, which can be under pharmacogenetic influence. Pharmacogenetics affecting AL metabolism, significantly influence the overall anti-malarial activity leading to variable therapeutic efficacy. This study focused on generic AL drugs used in malarial treatment as prescribed at health facilities and evaluated pharmacogenomic influences on their efficacy. METHODS: Patients who have been diagnosed with malaria and confirmed through RDT and microscopy were recruited in this study. Blood samples were taken on days 1, 2, 3 and 7 for parasite count and blood levels of lumefantrine, artemisinin, desbutyl-lumefantrine (DBL), and dihydroartemisinin (DHA), the active metabolites of lumefantrine and artemether, respectively, were analysed using established methods. Pharmacogene variation analysis was undertaken using iPLEX microarray and PCR-RFLP. RESULTS: A total of 52 patients completed the study. Median parasite density from day 1 to 7 ranged from 0-2666/µL of blood, with days 3 and 7 recording 0 parasite density. Highest median plasma concentration for lumefantrine and desbutyl lumefantrine, which are the long-acting components of artemisinin-based combinations, was 4123.75 ng/mL and 35.87 ng/mL, respectively. Day 7 plasma lumefantrine concentration across all generic ACT brands was ≥ 200 ng/mL which potentially accounted for the parasitaemia profile observed. Monomorphism was observed for CYP3A4 variants, while there were observed variations in CYP2B6 and CYP3A5 alleles. Among the CYP3A5 genotypes, significant differences in genotypes and plasma concentration for DBL were seen on day 3 between 1/*1 versus *1/*6 (p = 0.002), *1/*3 versus *1/*6 (p = 0.006) and *1/*7 versus *1/*6 (p = 0.008). Day 7 plasma DBL concentrations showed a significant difference between *1/*6 and *1/*3 (p = 0.026) expressors. CONCLUSIONS: The study findings show that CYP2B6 and CYP3A5 pharmacogenetic variations may lead to higher plasma exposure of AL metabolites.


Sujet(s)
Antipaludiques , Association d'artéméther et de luméfantrine , Artémisinines , Association médicamenteuse , Éthanolamines , Fluorènes , Humains , Antipaludiques/usage thérapeutique , Antipaludiques/pharmacocinétique , Association d'artéméther et de luméfantrine/usage thérapeutique , Femelle , Éthanolamines/usage thérapeutique , Éthanolamines/pharmacocinétique , Adolescent , Fluorènes/usage thérapeutique , Fluorènes/pharmacocinétique , Fluorènes/pharmacologie , Artémisinines/usage thérapeutique , Artémisinines/pharmacocinétique , Mâle , Ghana , Adulte , Jeune adulte , Enfant , Enfant d'âge préscolaire , Adulte d'âge moyen , Paludisme à Plasmodium falciparum/traitement médicamenteux , Paludisme à Plasmodium falciparum/parasitologie , Médicaments génériques/usage thérapeutique , Résultat thérapeutique , Pharmacogénétique , Sujet âgé , Nourrisson
19.
Molecules ; 29(7)2024 Apr 02.
Article de Anglais | MEDLINE | ID: mdl-38611871

RÉSUMÉ

Oleoylethanolamide (OEA) and palmitoylethanolamide (PEA) are endogenous lipids that act as agonists of the peroxisome proliferator-activated receptor α (PPARα). Recently, an interest in the role of these lipids in malignant tumors has emerged. Nevertheless, the effects of OEA and PEA on human neuroblastoma cells are still not documented. Type I interferons (IFNs) are immunomodulatory cytokines endowed with antiviral and anti-proliferative actions and are used in the treatment of various pathologies such as different cancer forms (i.e., non-Hodgkin's lymphoma, melanoma, leukemia), hepatitis B, hepatitis C, multiple sclerosis, and many others. In this study, we investigated the effect of OEA and PEA on human neuroblastoma SH-SY5Y cells treated with IFNß. We focused on evaluating cell viability, cell proliferation, and cell signaling. Co-exposure to either OEA or PEA along with IFNß leads to increased apoptotic cell death marked by the cleavage of caspase 3 and poly-(ADP ribose) polymerase (PARP) alongside a decrease in survivin and IKBα levels. Moreover, we found that OEA and PEA did not affect IFNß signaling through the JAK-STAT pathway and the STAT1-inducible protein kinase R (PKR). OEA and PEA also increased the phosphorylation of p38 MAP kinase and programmed death-ligand 1 (PD-L1) expression both in full cell lysate and surface membranes. Furthermore, GW6471, a PPARα inhibitor, and the genetic silencing of the receptor were shown to lower PD-L1 and cleaved PARP levels. These results reveal the presence of a novel mechanism, independent of the IFNß-prompted pathway, by which OEA and PEA can directly impair cell survival, proliferation, and clonogenicity through modulating and potentiating the intrinsic apoptotic pathway in human SH-SY5Y cells.


Sujet(s)
Amides , Endocannabinoïdes , Éthanolamines , Neuroblastome , Acides oléiques , Humains , Neuroblastome/traitement médicamenteux , Antigène CD274 , Janus kinases , Récepteur PPAR alpha , Inhibiteurs de poly(ADP-ribose) polymérases , Facteurs de transcription STAT , Transduction du signal , Apoptose , Acides palmitiques/pharmacologie
20.
Bioresour Technol ; 401: 130733, 2024 Jun.
Article de Anglais | MEDLINE | ID: mdl-38670287

RÉSUMÉ

This study investigated the mediating effect of Triethanolamine on Fe@C-Rhodobacter sphaeroides hybrid photosynthetic system to achieve efficient biohydrogen production. The biocompatible Fe@C generates excited electrons upon exposure to light, releasing ferrum for nitrogenase synthesis, and regulating the pH of the fermentation environment. Triethanolamine was introduced to optimize the electron transfer chain, thereby improving system stability, prolonging electron lifespan, and facilitating ferrum corrosion. This, in turn, stimulated the lactic acid synthetic metabolic pathway of Rhodobacter sphaeroides, resulting in increased reducing power in the biohybrid system. The ternary coupling system was analyzed through the regulation of concentration, initial pH, and light intensity. The system achieved the highest total H2 production of 5410.9 mL/L, 1.29 times higher than the control (2360.5 mL/L). This research provides a valuable strategy for constructing ferrum-carbon-based composite-cellular biohybrid systems for photo-fermentation H2 production.


Sujet(s)
Éthanolamines , Hydrogène , Lumière , Rhodobacter sphaeroides , Rhodobacter sphaeroides/métabolisme , Hydrogène/métabolisme , Éthanolamines/métabolisme , Éthanolamines/composition chimique , Fer/composition chimique , Catalyse , Concentration en ions d'hydrogène , Carbone , Fermentation , Photosynthèse
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE
...